New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
We previously reported that the compound O‐2093 is a selective inhibitor of the reuptake of the endocannabinoid anandamide (AEA). We have now re‐examined the activity of O‐2093 in vivo and synthesized four structural analogs (O‐2247, O‐2248, O‐3246, and O‐3262), whose activity was assessed in: (a) binding assays carried out with membranes from cells overexpressing the human CB 1 and CB 2 receptors; (b) assays of transient receptor potential of the vanilloid type‐1 (TRPV1) channel functional activity (measurement of [Ca 2+]i); (c) [14 C]AEA cellular uptake and hydrolysis assays in rat basophilic leukaemia (RBL‐2H3) cells; (d) the mouse ‘tetrad’ tests (analgesia on a hot plate, immobility on a ‘ring’, rectal hypothermia and hypolocomotion in an open field); and (e) the limb spasticity test in chronic relapsing experimental allergic encephalomyelitis (CREAE) mice, a model of multiple sclerosis (MS). O‐2093, either synthesized by us or commercially available, was inactive in the ‘tetrad’ up to a 20 mg kg−1 dose (i.v.). Like O‐2093, the other four compounds exhibited low affinity in CB 1 (Ki from 1.3 to >10 μM) and CB 2 binding assays (1.3<Ki< 8 μM), low potency and efficacy in a TRPV1 functional assay (EC 50>10 μM), very low potency as fatty acid amide hydrolase (FAAH) inhibitors (IC 50>25 μM) and were inactive in the ‘tetrad’ up to a 30 mg kg−1 dose (i.v.). While O‐2247 and O‐2248 were poor inhibitors of [14 C]AEA cellular uptake (IC 50>40 μM), O‐3246 and O‐3262 were quite potent in this assay. O‐3246, which exhibits only a very subtle structural difference with O‐2093, is the most potent inhibitor of AEA uptake reported in vitro under our experimental conditions (IC 50=1.4 μM) and is 12‐fold more potent than O‐2093. When injected intravenously O‐3246 and O‐3262, again like O‐2093 and unlike O‐2247 and O‐2248, significantly inhibited limb spasticity in mice with CREAE. These data confirm the potential utility of selective AEA uptake inhibitors as anti‐spasticity drugs in MS and, given the very subtle chemical differences between potent and weak inhibitors of uptake, support further the existence of a specific mechanism for this process. British Journal of Pharmacology (2006) 147, 83–91. doi:10.1038/sj.bjp.0706418
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 1×
“…the levels of the two major endocannabinoids, arachidonoylethanolamide (anandamide) (AEA) (Devane et al., 1992) and 2-arachidonoylglycerol (2-AG) (Mechoulam et al., 1995; Sugiura et al., 1995) are regulated by specific biosynthetic and degradative reactions catalyzed by enzymes that have been…”
BackgroundSelf-citation2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125 · cited 9×
“…that are capable of selectively inhibiting the cellular reuptake of AEA (LopezRodriguez et al., 2003; Ortar et al., 2003) without interfering with other proteins nor with the major enzyme involved in the degradation of this compound, fatty acid amide hydrolase (FAAH) (Cravatt et al., 1996).”
BackgroundInfluentialThe endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090 · cited 5×
“…‘central’ cannabimimetic activity (as assessed here in the mouse ‘tetrad’ of tests), O-3246 and O-3262 can serve as templates for the development of a new generation of potent endocannabinoid uptake inhibitors with several potential therapeutic applications (see Di Marzo et al., 2004a for review).”
BackgroundInfluentialSelf-citationThe endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)
Smart, D., Gunthorpe, M. J., Jerman, J. C., Nasir, S., Gray, J., Muir, A. I., Chambers, J. K., Randall, A. D., & Davis, J. B. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703050 · Cited by 775
Cannabinoid physiology and pharmacology: 30 years of progress
Howlett, A. C., Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., & Porrino, L. J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.030 · Cited by 608 · cited 1×
“…two such receptors have been cloned, the CB1 and CB2 cannabinoid receptors (Howlett, 2002, for a review), and, together with endocanna- binoids, they have been implicated in several physiological and pathological conditions in mammals (Di Marzo et al., 2004a; Howlett et al., 2004, for reviews).”
BackgroundDe Petrocellis, L., Bisogno, T., Davis, J. B., Pertwee, R. G., & Di Marzo, V. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02082-2 · Cited by 347
Fegley, D., Kathuria, S., Mercier, R., Li, C., Goutopoulos, A., Makriyannis, A., & Piomelli, D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400997101 · Cited by 230 · cited 2×
“…and O-3262 exert little, if any, inhibition of AEA intracellular hydrolysis, which in RBL-2H3 cells is catalyzed by FAAH, confirm recent evidence (Fegley et al., 2004; Ligresti et al., 2004; OrtegaGutierrez et al., 2004) that this latter protein is not solely responsible for AEA cellular uptake,…”
BackgroundInfluentialMelck, D., Bisogno, T., De Petrocellis, L., Chuang, H.-H., Julius, D., Bifulco, M., & Di Marzo, V. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1105 · Cited by 188
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“…2004; Massi et al., 2004; Nithipatikom et al., 2004; Allister et al., 2005; EllertMiklaszewska et al., 2005; Herrera et al., 2005, 2006; Lombard et al., 2005; Powles et al., 2005; Sarfaraz et al., 2005; Vaccani et al., 2005; Carracedo et al., 2006; Grimaldi et al., 2006; Ligresti et al., 2006b).”
BackgroundTargeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
Self-citationThe Endocannabinoid System and Pain
Guindon, J., & Hohmann, A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824660 · Cited by 476
Di Marzo, V. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.02.010 · Cited by 368
Self-citationEndocannabinoids and the regulation of their levels in health and disease
Di Marzo, V., & Petrosino, S. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32803dbdec · Cited by 289
Self-citationCentonze, D., Bari, M., Rossi, S., Prosperetti, C., Furlan, R., Fezza, F., De Chiara, V., Battistini, L., Bernardi, G., Bernardini, S., et al. (2007) · Brain · doi:10.1093/brain/awm160 · Cited by 207
Metadata
- Authors
- Ligresti, A., Cascio, M. G., Pryce, G., Kulasegram, S., Beletskaya, I., De Petrocellis, L., Saha, B., Mahadevan, A., Visintin, C., Wiley, J. L., Baker, D., Martin, B. R., Razdan, R. K., & Di Marzo, V.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2006-01
- Volume
- 147
- Issue
- 1
- Pages
- 83-91
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2014266143
- Cited by
- 65
- References
- 9
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.